Health TrialsbyHealthPanel

The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM)

ConditionsHivSyphilisHBV
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
AgeNot listed
SponsorInstitut de Recherche pour le Developpement

About this trial

The TRI-MOM program aims to implement and evaluate a simplified (based on inexpensive rapid diagnostic tests), integrated (in governmental health facilities) and coordinated (between health care workers) strategy for the triple elimination of HIV, syphilis and HBV mother-to-child transmission (MTCT) in nine maternal and child health services, 5 in Burkina Faso and 5 in The Gambia.

The TRI-MOM program has two components:

1. an "intervention" component consisting of a pilot study to reinforce the antenatal screening and prevention of MTCT (PMTCT) capacities for the 3 targeted infections through the implementation of a simplified, integrated and coordinated strategy of triple elimination of MTCT. 2. an "evaluation" component which will assess the impact of the TRI-MOM strategy on PMTCT services, reduction of HBV MTCT and women empowerment.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Women attending a postnatal visit in one of the selected maternities (no maternal age limit)

Disqualifiers

Refusal to participate in the study

Unable to provide consent

Trial design

Design model

Single group

Treatments tested in this trial

  • TRI-MOM intervention

    Other intervention

    The TRI-MOM strategy includes 4 main activities: 1. Training of healthcare professionals in charge of maternal health (nurses, midwives and doctors in charge of maternal health services) 2. Triple screening of HIV, Syphilis and HBV by rapid diagnostic tests 3. Assessment and treatment of women positive for any of the 3 targeted infections 4. Raising awareness on MTCT among pregnant women visiting antenatal services and empowering women infected with at least one of the three infections

Treatment groups

2,800 Participants
are divided into 1 treatment group
Group A: TRI-MOMExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Coverage of the strategy in the study maternities before its implementation

Proportion of women screened for HIV, Syphilis and HBV during pregnancy

Time frame
Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)
2

Coverage of the strategy in the study maternities after its implementation

Proportion of women screened for HIV, Syphilis and HBV during pregnancy

Time frame
Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)

Secondary outcomes

1

Knowledge of the targeted infections before the strategy implementation

Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT

Time frame
Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)
2

Knowledge of the targeted infections after the strategy implementation

Proportion of women with a good level of knowledge (defined by a score) of the targeted infections (HIV, syphilis, and HBV) and of PMTCT

Time frame
Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)
3

Acceptability of the implemented strategy and PMTCT and preferences : screening refusal before the strategy implementation

Proportion of pregnant women who refuse the screening for any of the 3 targeted infections

Time frame
Assessed cross-sectionally using a questionnaire administered to women at baseline (before the implementation of the TRI-MOM strategy)
4

Acceptability of the implemented strategy and PMTCT and preferences : screening refusal after the strategy implementation

Proportion of pregnant women who refuse the screening for any of the 3 targeted infections

Time frame
Assessed cross-sectionally using a questionnaire administered to women at 12 months (after the implementation of the TRI-MOM strategy)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut de Recherche pour le Developpement

Lead sponsor

Centre Muraz

Collaborator

Medical Research Council

Collaborator

Institut Pasteur

Collaborator

REVS PLUS Burkina Faso

Collaborator

Young Gambian Mums Fund

Collaborator

National AIDS Control Program Gambia

Collaborator

Source ClinicalTrials.gov
Apply now